The lack of Medicaid expansion in the South is creating worse racial disparities in the U.S., according to researchers and medical providers discussing the HIV care cascade at CROI 2018.
Three video interviews with federal HIV leaders who shared perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.
Results from a proof-of-principle study in macaques showing that treatment with broadly neutralising antibodies might play a role in key stages for an HIV cure.
Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.
Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment
New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.
24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.
No HIV Evolution in Plasma or Lymph Nodes on Suppressive ART and No Impact From Further Intensification
Two studies presented at CROI 2018 support the idea that ART reaches everywhere in the body that it needs to, and that residual ongoing HIV replication comes from HIV infected cells that were archived before ART was started.
A Facebook Live interview with NIAID Division of AIDS director Carl Dieffenbach, Ph.D., about some of the key research findings presented during the first full day of sessions at CROI 2018.
A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.
Nearly 90 percent of participants in an open-label study of a vaginal ring infused with a drug to prevent HIV are using the monthly ring at least some of the time, according to data presented at CROI 2018.